| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Reslizumab (anti-IL-5)
CAS:241473-69-8
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14183
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Reslizumab
CAS:241473-69-8
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:reslizumab
CAS:241473-69-8
Remarks:Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe asthma aged 18 years and older, and with an
|
|
| | reslizumab Basic information |
| Product Name: | reslizumab | | Synonyms: | reslizumab;Sch 55700;Research Grade Reslizumab (DHC13601);Research Grade Reslizumab;Reslizumab (anti-IL-5) | | CAS: | 241473-69-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![reslizumab Structure]() |
| | reslizumab Chemical Properties |
| storage temp. | Store at 4°C,Do not freeze | | solubility | Soluble in DMSO | | form | Liquid | | color | Colorless to light yellow |
| | reslizumab Usage And Synthesis |
| Uses | Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2]. | | Clinical Use | Treatment of severe eosinophilic asthma | | in vivo | Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice[3].
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3]. | Animal Model: | Male B6D2F1/J mice weighing 20?25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3] | | Dosage: | 0?10 mg/kg | | Administration: | Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.) | | Result: | Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463). |
| | Drug interactions | Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | | IC 50 | IL-5: 91.1 pM (IC50) | | Metabolism | Reslizumab is believed to be degraded by enzymatic
proteolysis into small peptides and amino acids. As
reslizumab binds to a soluble target, linear non-targetmediated clearance is expected. | | References | [1] Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. DOI:10.4168/aair.2019.11.2.291
[2] Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. DOI:10.1111/all.14035
[3] Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90. DOI:10.1055/s-0031-1300502 |
| | reslizumab Preparation Products And Raw materials |
|